<DOC>
	<DOCNO>NCT01586260</DOCNO>
	<brief_summary>The purpose research study evaluate new investigational drug prevent reoccurrence neuroblastoma remission . This study drug call DFMO . The objective study monitor safety look efficacy DFMO . The safety propose dose regimen trial test on-going risk/benefit assessment study . A patient benefiting treatment , progress therapy , absence safety issue associate DFMO may continue treatment 27 cycle expectation overall clinical benefit . The procedure involve study include Medical history , Physical exam , Vital sign ( blood pressure , pulse , temperature ) , Blood test , Urine test , MRI CT scan tumor ( ) , MIBG scan , Bone marrow aspiration . All test procedure consider standard care population . Drug administration also part protocol , include investigational new drug call DFMO . The propose dosing regimen oral dose DFMO tablet two time day day study . There 27 cycle . Each cycle 28 day length .</brief_summary>
	<brief_title>Preventative Trial DFMO Patients With High Risk Neuroblastoma Remission</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>Age : 021 year time diagnosis . Diagnosis : histologic verification either time original diagnosis previous relapse high risk neuroblastoma . Disease Status : Neuroblastoma remission Greater 30 day completion cytotoxic biologic therapy le 120 day previous therapy . A negative urine pregnancy test require female subject child bear potential ( onset menses ≥13 year age ) . Both male female postpubertal study subject need agree use one effective birth control method treatment six month treatment stop . These method include total abstinence ( sex ) , oral contraceptive ( `` pill '' ) , intrauterine device ( IUD ) , levonorgestrol implant ( Norplant ) , medroxyprogesterone acetate injection ( Depoprovera shot ) . If one use , contraceptive foam condom recommend . ANC &gt; 500/μl platelet count &gt; 50,000/μl Organ Function Requirements : Subjects must adequate liver function define : AST ALT &lt; 10x upper limit normal Serum bilirubin must ≤ 2.0 mg/dl Serum creatinine base age/gender Informed Consent : All subject and/or legal guardian must sign informed write consent . Assent , appropriate , obtain accord institutional guideline Lansky score &lt; 60 % BSA ( m2 ) &lt; 0.25 Investigational Drugs : Subjects currently receive another investigational drug exclude participation . Anticancer Agents : Subjects currently receive anticancer agent eligible . Subjects must fully recover effect prior chemotherapy ( hematological bone marrow suppression effect ) . Infection : Subjects uncontrolled infection eligible infection judge well controlled opinion investigator . Subjects , opinion investigator , may able comply safety monitoring requirement study , compliance likely suboptimal , exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Neuroblastoma remission</keyword>
	<keyword>Relapsed Neuroblastoma</keyword>
	<keyword>Refractory Neuroblastoma</keyword>
</DOC>